CD8A and neoplasm: All vaccinated mice showed OVA-specific CD8+ T cells, evaluated by IFNγ ELISpot assay, starting from 8 days after immunization, corresponding to 14 days after tumor injection (837 ± 167 spot forming cells (SFC)/106 cells, mean ± SD) reaching a peak at 35 days (1064 ± 293 SFC/106 cells).